Exelixis is reporting that one of its experimental therapies for diabetic nephropathy failed to hit its primary endpoint in Phase II. The kidney disease is brought on by chronic diabetes. Researchers had hoped to see statistically significant results for XL784 in reducing proteinuria, excess protein in urine, compared to a placebo. XL784 is described as a potent small molecule inhibitor of MMP2 and ADAM10, metalloprotease enzymes that may play a role in renal fibrosis and impairment.
Under the terms of its development pact with GlaxoSmithKline, Exelixis will submit the data to Glaxo to see if the pharma company wants to take the drug as one of three drug candidates it has options on. In the meantime, Exelixis plans to continue to analyze the data to see how, and whether, it wants to pursue more research.
- check out the release on the trial data
Read more on: Exelixis | Diabetes | GlaxoSmithKline